Genomic profiling and the impact of MUC19 mutation in hepatoid adenocarcinoma of the stomach

作     者：Mengxuan Zhu Erbao Chen Shan Yu Chen Xu Yiyi Yu Xin Cao Wei Li Pengfei Zhang Yan Wang Baofeng Lian Shuirong Zhang Yueting Qu Lujia Huang Weiwei Shi Yuehong Cui Li Qian Tianshu Liu 

作者机构：Department of Medical OncologyZhongshan HospitalFudan UniversityShanghai 20032P.R.China Center of Evidence-based medicineFudan UniversityShanghai 20032P.R.China Hepato-Pancreato-Biliary SurgeryPeking University Shenzhen HospitalShenzhenGuangdong 518036P.R.China Department of PathologyZhongshan HospitalFudan UniversityShanghai 20032P.R.China Institute of Clinical ScienceZhongshan HospitalFudan UniversityShanghai 20032P.R.China Origimed Co.LtdShanghai 20032P.R.China Cancer centerZhongshan hospitalFudan UniversityShanghai 20032P.R.China 

出 版 物：《Cancer Communications》 (癌症通讯（英文）)

年 卷 期：2022年第42卷第10期

页      面：1032-1035页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：the Natural Science Foundation of Shanghai(No.19ZR1409500) National Natural Science Foundation of China(No.82172925) the ethics committee of Zhongshan Hospital(No.B2020-094R)and obtained patients’consent to participate 

主　　题：stomach adenocarcinoma hepato 

摘      要：Dear Editor,Hepatoid adenocarcinoma(HAC)is a rare pathological subtype of extrahepatic tumor,featured by hepatoid differentiation andα-fetoprotein(AFP)-production[1,2].Hepatoid adenocarcinoma of the stomach(HAS),accounting for 0.3%to 1.0%of all gastric cancers(GCs),has attracted increasing attention due to its high degree of malignancy[3].Compared with classic GC,HAS showed a higher rate of vascular invasion,lymph node metastasis,and liver metastasis,with only 9.0%survival rate at 5 years[4].Currently,there is no effective treatment for HAS,and little is known about its ***,we investigated the molecular features of HAS and identified potential therapeutic targets for HAS.